# C_2010280EN.01003601.xml

| 16.10.2010 | EN | Official Journal of the European Union | C 280/36 |
| --- | --- | --- | --- |

16.10.2010

EN

Official Journal of the European Union

C 280/36

---

Prior notification of a concentration

(Case COMP/M.5982 — CVCII/Advance Properties/Huvepharma)

Candidate case for simplified procedure

(Text with EEA relevance)

2010/C 280/10

| 1. | On 8 October 2010, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertakings Citigroup Venture Capital International Investment G.P. Limited (‘CVCII’, Jersey), controlled by Citigroup, Inc. (USA), and Advance Properties OOD (‘Advance Properties’, Bulgaria) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Huvepharma AD (‘Huvepharma’, Bulgaria), currently under sole control of Advance Properties, by way of purchase of shares. |
| --- | --- |

1.

On 8 October 2010, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which the undertakings Citigroup Venture Capital International Investment G.P. Limited (‘CVCII’, Jersey), controlled by Citigroup, Inc. (USA), and Advance Properties OOD (‘Advance Properties’, Bulgaria) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Huvepharma AD (‘Huvepharma’, Bulgaria), currently under sole control of Advance Properties, by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:






  — | Citigroup: provision of financial services including banking services, brokerage and the management of private equity funds, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

Citigroup: provision of financial services including banking services, brokerage and the management of private equity funds,

| — | Advance Properties: investments in the fields of pharmaceuticals, real estate, energy and shipping businesses, |
| --- | --- |

—

Advance Properties: investments in the fields of pharmaceuticals, real estate, energy and shipping businesses,

| — | Huvepharma: pharmaceuticals with a focus on animal health and nutrition products. |
| --- | --- |

—

Huvepharma: pharmaceuticals with a focus on animal health and nutrition products.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.5982 — CVCII/Advance Properties/Huvepharma, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.5982 — CVCII/Advance Properties/Huvepharma, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

1

(2)  OJ C 56, 5.3.2005, p. 32 (‘Notice on a simplified procedure’).

2

---